Characterization of a vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate

Vaccine

Volumn 20, Issue 19-20, 2002, Pages 2485-2493

  Lin, Ya Ching ^a   Wu, Cheng Nan ^a,b   Shih, Shin Ru ^c   Ho, Mei Shang ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

EV71; Inactivated virus; Vero cell adapted virulent strain

Indexed keywords

ANTISERUM; INACTIVATED VACCINE; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; ENTEROVIRUS 71; GENETIC STABILITY; GROWTH RATE; LD 50; MOUSE; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TISSUE CULTURE; VACCINE PRODUCTION; VERO CELL; VIROGENESIS; VIRUS CHARACTERIZATION; VIRUS ISOLATION; VIRUS PLAQUE; VIRUS STRAIN; VIRUS TITRATION; VIRUS VIRULENCE; ANIMAL; BAGG ALBINO MOUSE; CERCOPITHECUS; CULTURE MEDIUM; ENTEROVIRUS; FEMALE; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; PATHOGENICITY; SERODIAGNOSIS; VIRULENCE; VIRUS CULTURE;

ANIMAL; CERCOPITHECUS AETHIOPS; CULTURE MEDIA, SERUM-FREE; ENTEROVIRUS; FEMALE; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PLAQUE ASSAY; SUPPORT, NON-U.S. GOV'T; VACCINES, INACTIVATED; VERO CELLS; VIRAL VACCINES; VIRULENCE; ANIMALS;

EID: 0037035859     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00182-2     Document Type: Article

References (33)

1. An apparently new enterovirus isolated from patients with disease of the central nervous system
2. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria
3. Molecular detection of enterovirus from an outbreak of hand, foot and mouth disease in Malaysia in 1991
4. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group
5. Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia
6. Role of enterovirus 71 in acute flaccid paralysis after the eradication of poliovirus in Brazil
7. First fatal case of enterovirus 71 infection in Hong Kong
8. Pathologic studies of fatal cases in outbreak of hand, foot, and mouth disease, Taiwan
9. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia
10. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: Clinical and pathological characteristics of the disease. For the Outbreak Study Group
11. Enterovirus 71 infection and neurologic complications
12. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with inactivated virus and subunit VP1 vaccine
13. Genetic analysis of enterovirus 71 isolated from fatal and non-fatal cases of hand foot, and mouth disease during an epidemic in Taiwan
14. A simple method of estimating fifty percent endpoints
15. Improvement of enterovirus neutralization by treatment with sodium deoxycholate or chloroform
16. Neutralization of aggregated strains of enterovirus 71 and echovirus type 4 in RD and Vero or GMK-AH1 cells
17. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: Impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine
18. Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains
19. 1980-1995: Suggestion of increased risk of vaccine associated poliomyelitis
20. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine
21. Survey of cell lines in the American type culture collection for bovine viral diarrhea virus
22. Prevalence of bovine viral diarrhea virus genotype and antibody against those viral genotypes in fetal bovine serum
23. Establishment and characterization of porcine kidney cell line, FS-L3, which forms unique multicellular domes in serum-free culture
24. Identification of a single amino acid residue in the capsid protein VP1 of coxsackievirus B4 that determines the virulence phenotype
25. Genetics of coxsackievirus virulence
26. A point mutation in VP1 of coxsackievirus B4 alters antigenicity
27. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge
28. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus
29. Construction, replication, and immunogenic properties of a simian immunodeficiency virus expressing interleukin-2
30. Env-independent protection induced by live, attenuated simian immunodeficiency virus vaccines
31. Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV
32. Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain
33. Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy